Material Transfer Agreements

Caveats

• The materials described here are for research purposes only. Investigators interested in commercial or other applications should directly contact the originator of the material.
• The information accessible through this web page is believed to be accurate and the reagents have been successfully used for their intended purpose. However, this does not guarantee that all information is completely accurate or that any reagent is suitable for the recipient’s purpose.
• Access to cell lines and plasmids is only provided to investigators who have complete, approved material transfer agreements.
• NIH IRP Guidelines for the Availability of Transgenic/Knockout Animals

ploxPFLPneo

The Transgenic Core has received permission from Dr. James Shayman to distribute the ploxPFLPneo plasmid. This plasmid contains two loxP sites and a neo cassette flanked by FRT sites.  Thanks go to Dennis Larkin for the annotated ploxPFLPneo map. Use these plasmids to construct a conditional allele by placing your target exon between the two loxP sites. Subsequently FLP mediated excision will delete the neo cassette, leaving behind a single FRT site. Do not position any of the elements in the plasmid in splicing sequences or conserved non-coding sequences or other sequence important for normal gene expression. Cre mediated expression will then delete the targeted exon and leave behind a loxP site and a FRT site.

Before we can distribute the ploxPFLPneo plasmid we need a brief letter addressed to Dr. Shayman stating that the ploxPFLPneo plasmid will be used for research purposes only. This will allow us to track how many people are using his vector. All publications which include data derived from the use of this plasmid should acknowledge Dr. Shayman for making the plasmid available and reference this paper: Hiraoka M, Abe A, Lu Y, Yang K, Han X, Gross RW, Shayman JA. 2006. Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol. 26:6139-48. Our FAX number is 734-936-2622. Include your mailing address, telephone number and Federal Express account number and we will send you the plasmid. An example letter follows:

Dr. James Shayman                                                                        Download ploxPFLPneo MAP
University of Michigan Medical School                                            Download ploxPFLPneo  SEQUENCE
Department of Internal Medicine
1150 West Medical Center Drive
Ann Arbor, MI 48109

Dear Dr. Shayman,

We wish to use the ploxPFlpneo targeting vector in our gene targeting research project. The vectors will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid.

Sincerely,

Joe P.I.

pOG-Flpe6

The Transgenic Core has received permission from Dr. Francis Stewart to distribute the pOG-Flpe6 plasmid. The plasmid was described in Buchholz F, Angrand PO, Stewart AF. 1998. Improved properties of FLP recombinase evolved by cycling mutagenesis. Nat Biotechnol 1998 Jul;16(7):657-662. See also http://www.biologie.tu-dresden.de/stewart/index.htm Here is his note regarding this plasmid:

“If you are receiving pOG-Flpe6, please note the three following points –

“1. One of the 4 a.a changes in Flpe as published (P2S) is not in pOG-Flpe6. It was complicated to clone this into the pOG vector so, under pressure to get the revised version back to the journal (the referees wanted a functional test in a mammalian cell line) we tested pOG-Flpe6 without this change and found it to be the best vector (of 6 variations) in both 293 and ES cells. We think that P2S is probably a mutation that was selected in our E. coli-based evolution strategy because it conveys increased protein stability on Flp in E. coli. This is because it is known that the initiating methionine of Flp is processed off in E. coli exposing it to the N-terminal protein stability rules defined by Varshavsky. Also, the N-terminae of other Flp-type recombinases is quite variable and it is unlikely that this region plays any functional role. We are using this plasmid to delete FRT flanked selectable markers in ES cells.”

“2. I ask for one consideration from all who receive Flpe. We are currently generating, hopefully, a Flp deletor mouse line and are trying both pOG-Flpe6 and phubac-Flpe6. If you make a Flp deletor line (i.e. a mouse line that expresses Flpe so that it can be crossed to other lines to remove FRT cassettes in a ubiquitous manner), then I ask that this be collaborative with my lab. Any other use of Flpe is entirely yours. Obviously you can ignore this request, but I think it reasonable – I want to guarantee value to those in my lab doing this Flp deletor work.”

“3. These reagents are completely available to anybody. You are free to pass them on without any need to ask permission. (But for Flpe, please mention point 2).”

Before we can distribute pOG-Flpe6  we need a brief letter addressed to Dr. Stewart stating that the pOG-Flpe6 vector will be used for research purposes only. We will use your letter to track how many people are using his vector. All publications which include data derived from the use of this plasmid should acknowledge Dr. Stewart for making pOG-Flpe6 available. Our FAX number is 734-936-2622. Include your mailing address, telephone number and Federal Express account number and we will send you the plasmid. An example letter follows:

Dr. A. Francis Stewart, Ph.D.                                                              Download pOG-Flpe6 Sequence
University of Technology, Dresden                                                      Download pOG-Flpe6 MAP
Biotec, Genomics
Tatzberg 47 – 51
01307 Dresden
Germany

I wish to use the pOG-Flpe6 targeting vector in my research . The vector will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid. I will reference Buchholz et al., 1998 regarding the vector.

Sincerely,

Joe or Jane P.I.

pPNT

The Transgenic Core has received permission from Dr. Richard Mulligan to distribute the pPNT gene targeting vector to interested investigators. Details on pPNT construction are in Tybulewicz, VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. 1991. Neonatal Lethality and Lymphopenia in Mice with a Homozygous Disruption of the c-abl Proto-Oncogene. Cell 65:1153-1163.

Before we can distribute pPNT we need a brief letter addressed to Dr. Mulligan stating that the pPNT vector will be used for research purposes only. We will use your letter to track how many people are using his vector. All publications which include data derived from the use of this plasmid should acknowledge Dr. Mulligan for making pPNT available. Our FAX number is 734-936-2622. Include your mailing address, telephone number and Federal Express account number and we will send you the plasmid. An example letter follows:

Dr. Richard Mulligan                                                                          Download pPNT/pPN2T/pPN2T-HGterm SEQUENCES
Children’s Hospital                                                                             Download pPNT MAP
300 Longwood Avenue
Boston, MA 02115

Dear Dr. Mulligan,

We wish to use the pPNT targeting vector in our gene targeting research project. The vector will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid. I will reference Tybulewicz et al., 1991 regarding the vector.

Sincerely,

Joe or Jane P.I.

pPN2T & pPN2T-HGterm

The Transgenic Core has received permission from Dr. Chris Paszty to distribute the pPN2T and pPN2T-HGterm vectors to interested investigators. Details on pPN2T vector construction are in Paszty C, Mohandas N, Stevens ME, Loring JF, Liebhaber SA, Brion CM, Rubin EM. 1995. Lethal alpha-thalassaemia created by gene targeting in mice and its genetic rescue. Nat Genet. 11:33-39 and pPN2T-HGterm construction is described in Zhu Y, Paszty C, Turetsky T, Tsai S, Kuypers FA, Lee G, Cooper P, Gallagher PG, Stevens ME, Rubin E, Mohandas N, Mentzer WC. 1999. Stomatocytosis is absent in “stomatin”-deficient murine red blood cells. Blood. 93:2404-2410. Before we can distribute the pPN2T and pPN2T-HGterm vectors we need a brief letter addressed to Dr. Paszty stating that the pPN2T and pPN2T-HGterm vectors will be used for research purposes only. This will allow us to track how many people are using his vectors. All publications which include data derived from the use of this plasmid should acknowledge Dr. Paszty for making the plasmids available. Our FAX number is 734-936-2622. Include your mailing address, telephone number and Federal Express account number na d we will send you the plasmid. An example letter follows:

Chris Paszty                                                                  Download pPNT/pPN2T/pPN2T-HGterm SEQUENCES
Amgen Inc.
Dept. of Molecular Genetics
One Amgen Center, MS 14-1-B
Thousand Oaks, CA  91320-1789

Dear Dr. Paszty,

We wish to use the pPN2T  and pPN2T-HGterm targeting vectors in our gene targeting research project. The vector will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid. I will reference the appropriate publication describing the vector(s).

Sincerely,

Jane or Joe P.I.

pnlacf

The Transgenic Core has received permission from Richard Palmiter to distribute the pnlacf plasmid to interested investigators. The pnlacf plasmid has a nuclear localized beta galactosidase gene that can be used as a reporter gene.

Before we can distribute pnlacf we need a brief letter addressed to Dr. Palmiter stating that the pnlacf plasmid will be used for research purposes only. All publications which include data derived from the use of this plasmid should acknowledge Dr. Palmiter for making pnlacF available.  Our FAX number is 734-936-2622. Include your mailing address, telephone number and Federal Express account number na d we will send you the plasmid. An example letter follows:

Dr. Richard Palmiter                                                                     Download pnlacf SEQUENCE
University of Washington                                                              Download pnlacf MAP
Howard Hughes Medical Institute
Box 357370
Seattle, Washington 98195-7370

Dear Dr. Palmiter,

We wish to use the pnlacf plasmid in our research project. The plasmid will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid.

Sincerely,

Joe or Jane P.I.

pnlacfNotINeo

The Transgenic Core has received permission from Dr. Steven Domino to distribute the pnlacfNotINeo gene targeting vector to interested investigators. Details on pnlacfNotINeo construction are in Domino SE, Zhang L, Gillespie PJ, Saunders TL, Lowe JB. Deficiency of reproductive tract alpha(1,2)fucosylated glycans and normal fertility in mice with targeted deletions of the FUT1 or FUT2 alpha(1,2)fucosyltransferase locus. Mol. Cell Biol. 21:8336-45.

Before we can distribute pnlacfNotINeo we need a brief letter addressed to Dr. Domino stating that the pnlacfNotINeo vector will be used for research purposes only. We will use your letter to track how many people are using his vector. All publications which include data derived from the use of this plasmid should acknowledge Dr. Domino for making pnlacfNotINeo available. Our FAX number is 734-936-2622. Include your mailing address, telephone number and Federal Express account number and we will send you the plasmid. An example letter follows:

Dr. Steven Domino                                                                        Download pnlacfNotINeo SEQUENCE
Department of Obstetrics and Gynecology
6428 Medical Science Bldg. I
1150 West Medical Center Dr.
The University of Michigan
Ann Arbor, MI 48109-0617

 E-mail: sedomino@med.umich.edu.

Dear Dr. Domino,

We wish to use the pnlacfNotINeo targeting vector in our gene targeting research project. The vector will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid. I will reference Domino et al., 2001 regarding the vector.

Sincerely,

Joe or Jane P.I.

pNZTK2

For University of Michigan Investigators: The Transgenic Core has received permission from Richard Palmiter to distribute the pNZTK2 targeting vector to interested investigators. This vector has neor, HSV-TK, and beta- galactosidase cassettes. It is designed to facilitate the construction of gene targeting vectors that place beta-galactosidase under the control of the endogenous gene promoter. Before we can distribute pNZTK2, the investigator needs to contact Dr. Palmiter and obtain a completed materials transfer agreement from him. Simply send a brief letter addressed to Dr. Palmiter stating that the pNZTK2 plasmid will be used for research purposes only. All publications which include data derived from the use of this plasmid should acknowledge Dr. Palmiter for making pNZTK2 available. An example letter follows:

For Other Investigators: Contact Dr. Palmiter Directly and ask him to send you the plasmid.

Dr. Richard Palmiter                          FAX (206) 543-0858               Download pNZTK2 Partial Sequence
University of Washington                                                                  Download pNZTK2 Map
Howard Hughes Medical Institute
Box 357370
Seattle, Washington 98195-7370

Dear Dr. Palmiter,

We wish to use the pNZTK2 plasmid in our research project. The plasmid will be used for research purposes only. I agree to acknowledge and thank you as the source of the plasmid.

Sincerely,

Jane or Joe P.I.

pflox

For University of Michigan Investigators: The Transgenic Core has received permission from Jamey Marth to distribute the pflox vector to interested investigators. It is designed to simplify the insertion of loxP sites in genes. Before we can distribute pflox, investigators need to contact Dr. Marth and obtain a completed materials transfer agreement from him. Simply send a letter addressed to Dr. Marth stating that the pflox vector will be used for research purposes only. I suggest that you FAX him the form letter below after transferring it to your letterhead. Bring your copy of the Material Transfer form to the Transgenic Core and we will provide you with the vector.

For Other Investigators: Contact Dr. Marth Directly and ask him to send you the plasmid.

Dr. Jamey Marth                                                    FAX (858) 534-6724         Download pflox Sequence
Professor of Cellular and Molecular Medicine                                                Download pflox MAP
Associate Investigator, Howard Hughes Medical Institute
University of California San Diego
Howard Hughes Medical Institute – 0625
9500 Gilman Drive
La Jolla, California 92093-0625

Dear Dr. Marth,

I wish to use the pflox vector in my research. It will not be used for commercial purposes and I will not distribute it without your consent. I will acknowledge you as the source of the pflox vector in any publications resulting from its use. I will cite your paper “Chui D, Oh-Eda M, Liao YF, Panneerselvam K, Lal A, Marek KW, Freeze HH, Moremen KW, Fukuda MN, Marth JD. 1997. Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis. Cell 90:157-167.” Please send me an HHMI Materials Transfer Agreement so that I may complete it and receive the plasmid from Dr. Thom Saunders at the University of Michigan Transgenic Animal Model Core.

Sincerely yours,

Joe or Jane P.I.

pMC-Cre

For University of Michigan Investigators: The Transgenic Core has received the pMC-Cre vector from Dr. Klaus Rajewsky to distribute to interested investigators. It is designed for the expression of the Cre enzyme in cells and carries a nuclear localization signal. Before we can distribute pMC-Cre, investigators need to contact Dr. Dr. Klaus Rajewsky and obtain permission from him to use pMC-Cre. Simply send a letter addressed to Dr. Rajewsky stating that the pMC-Cre vector will be used for research purposes only and that the University of Michigan has obtained permission to use Cre/LoxP materials for research purposes. I suggest that you FAX him the form letter below after transferring it to your letterhead. Bring your copy of the Material Transfer form to the Transgenic Core and we will provide you with the vector.

For Other Investigators: Contact Dr. Rajewsky Directly and ask him to send you the plasmid.

Dr. Klaus Rajewsky                          Download pMC-Cre Sequence
Professor of Pathology                    Download pMC-Cre MAP
Harvard Medical School
The CBR Insitute for Biomedical Research
Warren Alpet Building
200 Longwood Ave.
Boston, MA 02115

FAX: 617-278-3129

Dear Dr. Rajewsky,

I wish to use the pMC-Cre vector in my research. It will not be used for commercial purposes and I will not distribute it without your consent. I will acknowledge you as the source of the pMC-Cre vector in any publications resulting from its use. I will cite the paper “Gu H, Zou YR, Rajewsky K. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell. 73:1155-1164.” The University of Michigan has obtained permission from the Du Pont company to use Cre/LoxP technology for research purposes. Please send me an materials transfer agreement so that I may complete it and receive the plasmid from Dr. Thom Saunders at the University of Michigan Transgenic Animal Model Core.

Sincerely yours,

Joe or Jane P.I.

Useful information on the application of Cre recombinase technology can be found at Andras Nagy’s web site.

pACN

For University of Michigan Investigators: The Transgenic Core has received the pACN vector from Dr. Mario Capecchi. It is designed to express the Cre recombinase and to then delete itself by Cre mediated recombination in the cells  which express it. Please contact Dr. Mario Capecchi to obtain permission from him to use pACN in  your research. Simply send a letter addressed to Dr. Capecchi stating that the pACN vector will be used for research purposes only. I suggest that you FAX him the form letter below after transferring it to your letterhead. Bring your copy of the Material Transfer form to the Transgenic Core and we will provide you with the vector.

For Other Investigators: Contact Dr. Capecchi Directly and ask him to send you the plasmid.

Dr. Mario Capecchi                          Phone: 801-581-4422              Download the pACN MAP
Department of Human Genetics                                                       pACN Sequence
Eccles Institute of Human Genetics
University of Utah
15 North 2030 East, Room 2100
Salt Lake City, UT 84112-5330

Dear Dr. Capecchi,

I wish to use the pACN vector in my research. It will not be used for commercial purposes and I will not distribute it without your consent. I will acknowledge you as the source of the pflox vector in any publications resulting from its use. I will cite your paper Bunting M, Bernstein KE, Greer JM, Capecchi MR, Thomas KR. Targeting genes for self-excision in the germ line. Genes Dev. 1999 Jun 15;13(12):1524-8.Please send me an HHMI Materials Transfer Agreement so that I may complete it and receive the plasmid from Dr. Thom Saunders at the University of Michigan Transgenic Animal Model Core.

Sincerely yours,

Joe or Jane P.I.

Pat5

The Transgenic Core  generated Pat5 ES cells from 129X1/SvJ mice. To date three different genes have been targeted in Pat5 ES cells and published (Chen et al., 2002; Domino et al. 2001). This mouse embryonic stem cell line is available for use at low passage. The Pat5 cell line was isolated from a blastocyst obtained by  mating 129X1/SvJ mice  from The Jackson Laboratory.Immunosurgery was performed on the blastocyst to eliminate trophectoderm cells as described (Solter and Knowles, 1975). The inner cell mass cells were established in tissue culture on feeder cells prepared from primary mouse embryo fibroblasts. Pat5 ES cells are cultured in high glucose Dulbeccoís Minimal Essential Medium, supplemented with 15% fetal bovine serum, 1 uM beta-mercaptoethanol, 4 mM glutamine, penicillin (50 I.U. /ml), streptomycin (50 ug /ml) and 1000 U/ml recombinant leukemia inhibitory factor (ESGRO, Chemicon). Electroporation of Pat5 ES cells with the targeting vector and selection for clones was carried essentially as described in Kendall et al. (1995).

Chen C, Bharucha V, Chen Y, Westenbroek RE, Brown A, Malhotra JD, Jones D, Avery C, Gillespie PJ 3rd, Kazen-Gillespie KA, Kazarinova-Noyes K, Shrager P, Saunders TL, Macdonald RL, Ransom BR, Scheuer T, Catterall WA, Isom LL. Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits. Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17072-7.

Domino SE, Zhang L, Gillespie PJ, Saunders TL, Lowe JB. Deficiency of reproductive tract alpha(1,2)fucosylated glycans and normal fertility in mice with targeted deletions of the FUT1 or FUT2 alpha(1,2)fucosyltransferase locus. Mol Cell Biol. 2001 Dec;21(24):8336-45.

Kendall, SK, Samuelson, LC, Saunders, TL, Wood, RI, Camper, SA. 1995. Targeted Disruption of the Pituitary Glycoprotein Hormone alpha-subunit Produces Hypogonadal and Hypothyroid Mice. Genes Dev. 9:2007-2019.

Solter D, Knowles BB. 1975. Immunosurgery of mouse blastocyst. Proc Natl Acad Sci U S A 72:5099-102.

If you would like to obtain Pat5 ES cells from please read the Pat5 Material Transfer Agreement and contact Thom Saunders about finalizing the transfer.

Pat5 Chimeras

R1

The mouse embryonic stem (ES) cell line R1 was developed in the laboratories of Drs. Janet Rossant and John Roder at Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, Canada. This cell line was derived from a cross between 129X1/SvJ and 129S1/Sv-+p+Tyr-cKitlSl-J/+ mice. The derivation of the R1 cell line is described in: Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. 1993. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl. Acad. Sci. 90:8424-8428.

For University of Michigan Investigators: We have streamlined the Material Transfer Agreement process for University of Michigan investigators for the R1 mouse embryonic stem cells. It is still necessary for each investigator to complete a University Material Transfer Form (MTF). The MTF should be completed and signed by the University investigator then sent through the signature approval pathway along with Schedule A to the original Material Transfer Agreement executed between Mt. Sinai and UM.  Schedule A should also be signed by the investigator. Upon its arrival at the Division of Research Development and Administration (DRDA) along with the MTF, Schedule A will be signed on behalf of the University and sent to Terry Donaghue at Mt. Sinai. All publications which include data derived from the use of this cell line should acknowledge the contribution of Dr. Andras Nagy, Reka Nagy and Dr. Wanda Abramow-Newerly for making the R1 cell line available.

For Other Investigators: Investigators from other institutions who wish to utilize the R1 ES cells will need an agreement between Mt. Sinai and their respective institutions. Investigators interested in using the R1 cells should write to Mr. Terrence P. Donaghue to arrange for permission and the signing of a materials transfer agreement.

The letter should be addressed to :

OFFICE OF TECHNOLOGY TRANSFER & INDUSTRIAL LIAISON
MOUNT SINAI HOSPITAL
SAMUEL LUNENFELD RESEARCH INSTITUTE
Michael Hanna, Licensing Associate
600 University Ave.
Toronto, Ontario, Canada M5G 1X5
Tel. 416.586.4800 ext. 4752
Fax 416.586.8844
E-mail: hanna(at)mshri.on.ca

CJ7

The Transgenic Core has received permission from Dr. Thomas Gridley to distribute the CJ7 embryonic stem cell line to interested investigators for research use only. This cell line was derived from 129S1/SvImJ mice. All publications which include data derived from the use of this cell line should acknowledge Dr. Gridley for making CJ7 available. Before we can distribute CJ7 cells we need a brief letter addressed to Dr. Gridley stating that they will be used for research purposes only. This will allow us to track demand for the CJ7 ES cells An example letter follows:

Dr. Thomas Gridley
The Jackson Laboratory
600 Main Street
Bar Harbor, Maine 04609

Dear Dr. Gridley,

We wish to use the CJ7 embryonic stem cell line in our research project. The animals that we generate will be used for research purposes only. I agree to acknowledge you as the source of the cells and reference Swiatek, PJ, and Gridley T. 1993. Perinatal Lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Genes and Development 7:2071-2084 as the source of the cells.

Sincerely,

Joe or Jane P.I.

E14Tg2a clone4

The Transgenic Core has received E14Tg2a clone4 ES cells from Dr. Bill Skarnes. This cell line was derived from 129P2/OlaHsd mice. We have permission to distribute the E14Tg2a clone4 embryonic stem cell line to interested investigators for research use only. The cells were generously provided to the research community by Dr. Austin Smith at the University of Edinburgh. All publications which include data derived from the use of this cell line should acknowledge Dr. Smith for making E14Tg2a clone4 ES cells  available. Before we can distribute the cells we need a brief letter addressed to Dr. Smith stating that they will be used for research purposes only. This will allow us to track demand for the E14Tg2a clone4 ES cells. An example letter follows:

Dr. Austin Smith
Center for Genome Research
The University of Edinburgh
Roger Land Building
Edinburgh EH9 3JQ
United Kingdom

Dear Dr. Smith,

I wish to use the E14Tg2a clone4 embryonic stem cell line in my research project. The cells will be used for research purposes only. I agree to acknowledge you as the source of the cells.

Sincerely,

Joe or Jane P.I.

Bruce4

For University of Michigan Investigators: The Bruce4 mouse embryonic stem cell line was provided to the Transgenic Core by Colin Stewart. Unlike the other ES cell lines on this page, the Bruce4 cell line was derived from C57BL/6 mice. We have successfully obtained germline transmission for the unmodified Bruce4 cells and also with gene targeted Bruce4 clones. Please contact Dr. Stewart and obtain a material transfer agreement that allows you to use this ES cell line. An example letter follows.

For Other Investigators: Obtain the Bruce4 ES cell line directly from Dr. Stewart.

Dr. Colin Stewart
Cancer and Developmental Biology Laboratory
NCI-FCRDC
Building 539, Room 121A
P.O. Box B
Frederick, MD 21702-1201

FAX 301- 846-7117

Dear Dr. Stewart,

We wish to use the Bruce4 embryonic stem cell line in our research. It  will be used for research purposes only. I agree to acknowledge you as the source of the cells and to reference Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H. 1993. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol. Aug;5(8):957-964 as the origin of the cell line.

Sincerely,

Jane or Joe P.I.

D3

The Transgenic Core has received permission from Dr. Thomas Doetschman to distribute the D3 embryonic stem cell line to interested investigators for research use only. This cell line was derived from 129S2/SvPas mice. All publications which include data derived from the use of this cell line should acknowledge Dr. Doetschman for making D3 available. Before we can distribute D3 cells we need a brief letter addressed to Dr. Doetschman stating that they will be used for research purposes only. This will allow us to track demand for the D3 ES cells. An example letter follows:

Dr. Thomas Doetschman
Department of Molecular Genetics
College of Medicine
University of Cincinnati
Cincinnati, OH 45267

Dear Dr. Doetschman,

We wish to use the D3 embryonic stem cell line in our research. It and any gene targeted animals produced will be used for research purposes only. I agree to acknowledge you as the source of the cells and to reference Doetschman, TC, Eistetter, H, Katz, M, Schmidt, W, Kemler, R. 1985. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 87:27-45 as the origin of the cell line.

Sincerely,

Jane or Joe P.I.

NIH IRP GUIDELINES FOR THE AVAILABILITY OF TRANSGENIC/KNOCKOUT ANIMALS

Transgenic and gene “knockout” animals that have been developed using NIH IRP (intramural research program) funds and resources will be provided to other laboratories following publication of descriptions of the animals in the peer reviewed literature. It is an obligation of NIH intramural scientists to make such animals widely available for research purposes. This can be achieved by making arrangements to send breeding pairs to a central repository such as the Induced Mutant Resource at the Jackson Laboratory. This would assure the availability of clean, genetically characterized animals within a year’s time. An attempt should be made to reduce duplication of effort by setting up collaborative experiments whenever possible; however, this should not be used as a mechanism to inhibit the distribution of animals.

These guidelines for the IRP are now in agreement with those of the US Public Health Service (PHS) for the extramural community: “It is the policy of PHS to make available to the public the results and accomplishments of the activities that it funds…. Therefore, when these resources are developed with PHS funds and the associated research findings have been published or after they have been provided to the agencies under contract, it is important that they be made readily available for research purposes to qualified individuals within the scientific community. This policy applies to grants, cooperative agreements, and contracts.”

These guidelines supplement those already covered by the NIH Guide for other types of biological materials and resources. The NIH Guide for the Care amd Use of Laboratory Animals is available online.